Does anti-TNF-alpha have a role in the treatment of osteoporosis?

Bulletin of the NYU Hospital for Joint Diseases

Volumn 66, Issue 4, 2008, Pages 280-281

  McMahon, Mark S ^a,b   Ueki, Yasuyoshi ^a  

^a HARVARD UNIVERSITY   (United States)

^b Research and Education Building 413 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; DEOXYPIRIDINOLINE; OSTEOCALCIN; PROCOLLAGEN; RALOXIFENE; TELOPEPTIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; RADIOLOGY; SPINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; HUMANS; IMMUNOGLOBULIN G; OSTEOPOROSIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149271014     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Seriolo B, Paolino S, Sulli A, Cutolo M. [Are there any positive effects of TNF-alpha blockers on bone metabolism?] Reumatismo. 2006;58(3):199-205. (Italian).
2. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann NY Acad Sci. 2006;1069:420-7.
3. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford). 2005;44(12):1546-8.
4. Torikai E, Kageyania Y, Takahashi M, et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(6):761-4.
5. Demis E, Roux C, Breban M, Dougados M. Infliximab in spondylarthropathy - influence on bone density. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S185-6.
6. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1495-9.
7. Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis. 2005;64(8):1137-40.
8. Allali F, Breban M, Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis. 2003;62(4):347-9.
9. Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann NY Acad Sci. 2006;1068:543-56.
10. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100(9):2031-5.
11. Ueki Y, Lin C, Senoo M, et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in Sh3bp2 "Cherubism" mice. Cell. 2007;128:71-83.
12. Saidenberg-Kermanac'h N, Corrado A, et al. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone. 2004;35(5):1200-7.
13. Kastelan D, Kastelan M, Massari LP, Korsic M. Possible association of psoriasis and reduced bone mineral density due to increased TNF-alpha and IL-6 concentrations. Med Hypotheses. 2006;67(6):1403-5.